<DOC>
	<DOCNO>NCT01951560</DOCNO>
	<brief_summary>The purpose first part study determine safety tolerability ascend dos valproic acid ( also know Depacon ) administer intravenous infusion ( IV ) dose range 15 mg/kg 250 mg/kg healthy subject . The second part study also determine safety tolerability single ascending dos valproic acid administer IV trauma subject hemorrhagic shock .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Valproic Acid Healthy Volunteers ( Part 1 )</brief_title>
	<detailed_description>Part 1 study single center study intend assess safety tolerability valproic acid dosage 15 mg/kg , 30 mg/kg , 60 mg/kg , 90 mg/kg , 120 mg/kg , 150 mg/kg 180 mg/kg , 210 mg/kg 250 mg/kg . Up 72 healthy subject ( 9 dose group 8 subject ) receive single dos valproic acid placebo via 60-min IV infusion ratio 3:1 active drug : placebo . Part 2 study multicenter , double blind , placebo-controlled study trauma patient hemorrhagic shock able give consent severe trauma patient hemorrhagic shock legally authorize representative give consent . Up 12 patient ( 2 dose group 6 patient ) receive single dos valproic acid placebo via 60-min IV infusion ratio 2:1 active drug : placebo . The dose level Part 2 two high dos demonstrate acceptable safety profile base review safety data Part 1 .</detailed_description>
	<mesh_term>Shock , Hemorrhagic</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Male female volunteer age 18 65 year , inclusive , good health base medical history , physical examination , ECG , routine laboratory test ( blood chemistry , hematology , urinalysis , drug screen ) . 2 . Female subject must surgically sterilize postmenopausal . Criteria menopause surgical menopause ( hysterectomy , oophorectomy ) age &gt; 45 year absence menses great 12 month serum follicle stimulate hormone ( FSH ) elevation &gt; 25m IU/mL . ( mIU/mL unit use measure human chorionic gonadotropin ( hCG ) pregnancy test ) . Tubal ligation menses within past 12 month consider surgical sterilization . 3 . Negative urine pregnancy test female volunteer 4 . Body mass index ( BMI ) 18 kg/m2 30 kg/m2 5 . Subjects must nonsmoker 6 . Negative alcohol screen 7 . Willing able confined clinical research facility require protocol . 8 . Willing able comply investigational nature study able communicate well investigator . 9 . Ability comprehend willingness provide write informed consent accordance institutional regulatory guideline . 1 . Subjects evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy ; however , subject untreated , asymptomatic , seasonal allergy may enrol ) . 2 . Subjects aamylase &gt; 130 U/L lipase &gt; 300 U/L creatinine &gt; upper limit normal ( ULN ) 3 . Subjects &gt; 2times ULN aspartate aminotransferase ( AST ) alanine amino transferase ( ALT ) &gt; 1.5 time total bilirubin 4 . Subjects whose screen ECG demonstrate least one following : heart rate &gt; 100 bpm 30 minute , ( combination three graphical deflection see typical ECG call ( QRS ) ) &gt; 120 msec , correct QT interval ( QTc ) &gt; 440 msec male 450 msec female , prevalence rate ( PR ) &gt; 220 msec rhythm sinus rhythm , sinus bradycardia ( HR &lt; 40 bpm ) , sinus arrhythmia . 5 . Subjects history alcohol consumption exceed 14 drinks/week average within 6 month study entry . 6 . Subjects whose sit blood pressure 140/90 mmHg 2 evaluation least 10 minute apart screen . 7 . Subjects donate blood excess 500 mL within 60 day prior first dose study medication . 8 . Subjects positive result drug screen , hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) , human immunodeficiency ( HIV ) test 9 . Subjects use prescription nonprescription drug , vitamin , herbal supplement dietary supplement within 14 day prior first dose study medication . Subjects use acetaminophen dos &lt; 2 grams/day eligible study entry . 10 . Subjects treat investigational drug within 30 day . 11 . Subjects previously receive currently take valproic acid . 12 . Subjects history drug abuse . 13 . Subjects willing abstain consume product contain caffeine ( include chocolate ) , methyl xanthine , alcohol Day 1 end pharmacokinetics ( PK ) study ( day 4 part 1 subject ) . 14 . Subjects febrile illness within 5 day prior first dose study medication . 15 . Subjects inadequate venous access . 16 . Subjects vaccinate within 30 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>